Phase III pulmonary fibrosis drug trial fails

Phase III pulmonary fibrosis drug trial fails

By, Admin 9 June 2025

Overview

Bellerophon Therapeutics has announced it will close its Phase III study of INOpulse, its treatment for fibrotic Interstitial Lung Disease (fILD), after the trail failed to meet its primary endpoint.

About REBUILD clinical trial

  • The REBUILD clinical trial was designed as a randomised, double-blind, placebo-controlled Phase III study evaluating the safety and efficacy of INOpulse for the treatment of patients with fILD. 
  • A total of 145 fILD patients were enrolled and treated with either INOpulse at a dose of iNO45 or a placebo.
  • The primary endpoint was the change in moderate to vigorous physical activity (MVPA) as measured by actigraphy after 16 weeks of chronic treatment. 
  • iNO45 performed worse than placebo by 5.49 minutes per day.
  • The secondary endpoints demonstrated minimal difference between the two groups with none approaching statistical significance.

Statement from the CEO: Bellerophon

The REBUILD study did not match the outcomes we saw in the exploratory Phase II study in this patient population; however, the overall outcome of this pivotal validation study is conclusive and we do not see a path forward for continuing the REBUILD trial,” said Peter Fernandes, Bellerophon’s Chief Executive Officer.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!